Resmed Inc RSMDF
We take great care to ensure that the data presented and summarized in this overview for RESMED INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in RSMDF
Top Purchases
Top Sells
About RSMDF
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Insider Transactions at RSMDF
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 09
2024
|
Brett Sandercock Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,000
-1.05%
|
$244,000
$244.23 P/Share
|
Dec 04
2024
|
Peter C Farrell Director |
SELL
Open market or private sale
|
Direct |
2,000
-2.4%
|
$490,000
$245.65 P/Share
|
Dec 02
2024
|
Michael J Rider Global General Counsel |
SELL
Open market or private sale
|
Direct |
74
-0.81%
|
$18,352
$248.91 P/Share
|
Nov 29
2024
|
Michael J Rider Global General Counsel |
SELL
Bona fide gift
|
Direct |
173
-1.85%
|
-
|
Nov 27
2024
|
Michael J. Farrell Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
2,000
-100.0%
|
$498,000
$249.66 P/Share
|
Nov 27
2024
|
Michael J. Farrell Chief Executive Officer |
BUY
Bona fide gift
|
Indirect |
2,000
+50.0%
|
-
|
Nov 27
2024
|
Michael J. Farrell Chief Executive Officer |
SELL
Bona fide gift
|
Indirect |
2,000
-48.9%
|
-
|
Nov 22
2024
|
Justin Leong Chief Product Officer |
SELL
Open market or private sale
|
Direct |
6,160
-22.1%
|
$1,496,880
$243.09 P/Share
|
Nov 20
2024
|
Richard Sulpizio Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,083
+5.74%
|
-
|
Nov 20
2024
|
Desney Tan Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,083
+18.01%
|
-
|
Nov 20
2024
|
Ronald R Taylor Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,083
+4.37%
|
-
|
Nov 20
2024
|
Christopher Del Orefice Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,083
+44.51%
|
-
|
Nov 20
2024
|
Harjit Gill Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,083
+9.86%
|
-
|
Nov 20
2024
|
John Hernandez Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,083
+21.12%
|
-
|
Nov 20
2024
|
Jan De Witte Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,083
+12.18%
|
-
|
Nov 20
2024
|
Karen Drexler Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,083
+10.21%
|
-
|
Nov 20
2024
|
Carol Burt Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,083
+27.53%
|
-
|
Nov 20
2024
|
Peter C Farrell Director |
BUY
Grant, award, or other acquisition
|
Direct |
542
+0.65%
|
-
|
Nov 12
2024
|
Jan De Witte Director |
SELL
Open market or private sale
|
Direct |
796
-10.59%
|
$197,408
$248.81 P/Share
|
Nov 11
2024
|
Peter C Farrell Director |
SELL
Payment of exercise price or tax liability
|
Direct |
527
-0.63%
|
$132,804
$252.38 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 65.5K shares |
---|---|
Bona fide gift | 2K shares |
Exercise of conversion of derivative security | 134K shares |
Other acquisition or disposition | 9.63K shares |
Payment of exercise price or tax liability | 13.3K shares |
---|---|
Bona fide gift | 70.7K shares |
Open market or private sale | 220K shares |
Other acquisition or disposition | 9.63K shares |